Graft-versus-host disease : Part II. Management of cutaneous graft-versus-host disease - 14/03/12
, Amin M. Alousi, MD b, Edward W. Cowen, MD, MHSc c
Correspondence to: Sharon R. Hymes, MD, Department of Dermatology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd-434, Houston, TX 77030-4009.Abstract |
Dermatologists are ideally suited to manage the various cutaneous sequelae of graft-versus-host disease (GVHD) outlined in part I of this review. However, the complexity of the patient with GVHD, including comorbidities, potential drug interactions related to polypharmacy, and the lack of evidence-based treatment guidelines, are significant challenges to optimizing patient care. In this section, we will provide an outline for the role of the dermatologist in a multispecialty approach to caring for patients with GVHD.
Le texte complet de cet article est disponible en PDF.Key words : cyclosporine, extracorporeal photopheresis, graft-versus-host disease, hematopoietic cell transplantation, imatinib mesylate, mycophenolate mofetil, phototherapy, tacrolimus, rituximab
Abbreviations used : CNI, CSA, ECP, EV, GVHD, GVT, HCT, MMF, MSC, mTOR, MTX, NB-UVB, PUVA, PDGFR, SCC, TSS, UVA-1, UVR, Tregs, TSS
Plan
| Supported in part by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research. |
|
| Reprints not available from the authors. |
Vol 66 - N° 4
P. 535.e1-535.e16 - avril 2012 Retour au numéro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?